Colonic stent vs surgical resection of the primary tumor. Effect on survival from stage-IV obstructive colorectal cancer.


Journal

Revista espanola de enfermedades digestivas
ISSN: 1130-0108
Titre abrégé: Rev Esp Enferm Dig
Pays: Spain
ID NLM: 9007566

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 7 8 2020
medline: 29 6 2021
entrez: 7 8 2020
Statut: ppublish

Résumé

the impact of surgical primary tumor resection on survival of obstructive metastatic colorectal cancer remains controversial. The primary goal of this study was to analyze survival in patients with obstructive metastatic colorectal cancer after treatment with either resection surgery or a colonic stent. a prospective study was performed of all patients with stage-IV colorectal cancer and obstructive manifestations, diagnosed from 2005 to 2012 and managed with either resection surgery or a colonic stent. Cases with a perforation, abscess, right colon or distal rectal malignancy, multiple colorectal cancer or derivative surgery were excluded. a total of 95 patients were included, 49 were managed with resection surgery and 46 with a colonic stent. The colonic stent group had a higher Charlson index (9.5 ± 2.1 vs 8.6 ± 1.5, p = 0.01), a shorter time to oral intake (0.9 ± 1.1 vs 16.4 ± 53.5 days, p = 0.05), a shorter hospital stay (4 ± 4.8 vs 16.7 ± 15.5 days, p = 0.0001), less need for stomata (11.1 % vs 32.7 %, p = 0.01), fewer early complications (4.3 % vs 46.9 %, p = 0.0001) and more late complications (33.3 % vs 6.4 %, p = 0.001). Undergoing chemotherapy (p = 0.008) was the only independent factor related to increased survival. In the subgroup of patients managed with chemotherapy, surgical primary tumor resection was an independent factor associated with increased survival. both treatments are effective for resolving obstructive manifestations in patients diagnosed with stage-IV obstructive colorectal cancer. Resection surgery has no positive impact on survival and thus cannot be recommended as a therapy of choice.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
the impact of surgical primary tumor resection on survival of obstructive metastatic colorectal cancer remains controversial. The primary goal of this study was to analyze survival in patients with obstructive metastatic colorectal cancer after treatment with either resection surgery or a colonic stent.
MATERIAL AND METHODS METHODS
a prospective study was performed of all patients with stage-IV colorectal cancer and obstructive manifestations, diagnosed from 2005 to 2012 and managed with either resection surgery or a colonic stent. Cases with a perforation, abscess, right colon or distal rectal malignancy, multiple colorectal cancer or derivative surgery were excluded.
RESULTS RESULTS
a total of 95 patients were included, 49 were managed with resection surgery and 46 with a colonic stent. The colonic stent group had a higher Charlson index (9.5 ± 2.1 vs 8.6 ± 1.5, p = 0.01), a shorter time to oral intake (0.9 ± 1.1 vs 16.4 ± 53.5 days, p = 0.05), a shorter hospital stay (4 ± 4.8 vs 16.7 ± 15.5 days, p = 0.0001), less need for stomata (11.1 % vs 32.7 %, p = 0.01), fewer early complications (4.3 % vs 46.9 %, p = 0.0001) and more late complications (33.3 % vs 6.4 %, p = 0.001). Undergoing chemotherapy (p = 0.008) was the only independent factor related to increased survival. In the subgroup of patients managed with chemotherapy, surgical primary tumor resection was an independent factor associated with increased survival.
CONCLUSION CONCLUSIONS
both treatments are effective for resolving obstructive manifestations in patients diagnosed with stage-IV obstructive colorectal cancer. Resection surgery has no positive impact on survival and thus cannot be recommended as a therapy of choice.

Identifiants

pubmed: 32755149
doi: 10.17235/reed.2020.5701/2018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

694-700

Auteurs

Agustín Seoane Urgorri (A)

Aparato Digestivo, Hospital del Mar, España.

Esteban Saperas (E)

Aparato Digestivo, Hospital General de Catalunya, España.

Elena O'Callaghan Castella (E)

Aparato Digestivo, Hospital General de Catalunya, España.

Miguel Pera Román (M)

Cirugía General, Hospital del Mar, España.

Agnès Raga Gil (A)

Aparato Digestivo, Hospital del Mar, España.

Faust Riu Pons (F)

Aparato Digestivo, Parc de Salut Mar. Hospital del Mar, España.

Luis Barranco Priego (L)

Aparato Digestivo, Hospital del Mar, España.

Josep María Dedeu Cusco (JM)

Aparato Digestivo, Hospital del Mar, España.

Miguel Pantaleón Sánchez (M)

Aparato Digestivo, Hospital del Mar, España.

Xavier Bessa Caserras (X)

Aparato Digestivo, Hospital del Mar, España.

Marco Antonio Álvarez-González (MA)

Aparato Digestivo, Hospital del Mar, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH